Eisai

HATFIELD, England, December 5, 2011 - Eisai welcomes the launch of the UK Life Sciences Strategy.

HATFIELD, England, June 27, 2011 - Eisai today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for perampanel as a treatment for partial-onset seizures in patients with epilepsy.

HATFIELD, England, May 20, 2011 - Eisai announced today that 10 abstracts highlighting new study results in thyroid cancer, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 3 to June 7, 2011.

HATFIELD, England, May 17, 2011 - Eribulin (Halaven(R)) is today approved for use in Switzerland by Swissmedic, the Swiss Agency for Therapeutic Products, as a monotherapy treatment of patients with locally advanced and metastatic breast carcinoma with progression after prior therapy with an anthracycline, a taxane and capecitabine.[1] Breast cancer is the second most commonly diagnosed cancer worldwide and there are about 1.3 million new cases of the disease annually.[2] More than 5,000 Swiss women have the disease and approximately 1,400 are likely to die annually.[3] Eisai submitted a New Drug Application based on the results from a Phase II study (Study 211) of eribulin in order to deliver the medicine to patients as quickly as possible.

LONDON, March 22, 2011 - Eisai announced today that it has received approval from the European Commission for Halaven(TM) (Eribulin) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.